A Cancer Spheroid Array Chip for Selecting Effective Drug.

Area of Science:

• Biotechnology
• Cancer Research
• Drug Discovery

Background:

• Evaluating drugs targeting specific mutations like phosphor-epidermal growth factor receptor (p-EGFR) is crucial in cancer therapy.
• Traditional spheroid array chips present challenges in reagent handling and immunostaining, hindering efficient drug screening.
• Developing advanced platforms is necessary to overcome limitations in current cancer spheroid drug evaluation methods.

Purpose of the Study:

• To develop an improved cancer spheroid array chip for efficient drug evaluation targeting specific mutations.
• To overcome the limitations of tedious reagent replacement and potential damage to spheroids in existing array systems.
• To compare drug responses between spheroid models and single-cell models for enhanced drug candidate selection.

Main Methods:

• A cancer spheroid array chip was engineered using a modified micropillar and microwell structure.
• Cancer cells were encapsulated in alginate on micropillars to form spheroids over seven days.
• The chip facilitated simplified reagent replacement through a single-medium fill, preserving spheroid integrity.

Main Results:

• A 12x36 array chip successfully formed p-EGFR-overexpressing A549 lung cancer spheroids (>100 µm diameter) by day seven.
• The array was utilized for p-EGFR inhibition and cell viability assays against seventy drugs, including ten EGFR-targeting agents.
• Significant differences in drug response were observed between the spheroid model and the single-cell model.

Conclusions:

• The developed cancer spheroid array chip offers a more efficient and less damaging method for drug screening.
• Spheroid models demonstrate differential drug responses compared to single-cell models, suggesting increased resistance to certain drugs.
• This platform aids in narrowing down drug candidates by providing a more biologically relevant drug response profile.